Nuvectis Pharma Inc

NVCT

5.670USD

+0.020+0.35%

Close 11/06, 16:00（ET）Quotes delayed by 15 min

Nuvectis Pharma Inc's Score

Industry at a Glance

Industry Ranking

238 / 501

Overall Ranking

425 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 6 analysts

Buy

Current Rating

18.167

Target Price

+221.53%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Nuvectis Pharma Inc Highlights

StrengthsRisks

Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is developing two drug candidates: NXP800 and NXP900. NXP800 is an oral small molecule GCN2 activator, which is in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP800 activates the GCN2 kinase inducing inhibition of cap-dependent protein translation and activation of the integrated stress response leading to cancer cell death. NXP900 is a targeted-therapy, small molecule drug candidate that inhibits the proto-oncogene c-Src (SRC) and YES1 kinases, which is undergoing a Phase 1a dose escalation study. SRC is aberrantly activated in many cancer types, including solid tumor cancers such as breast, colon, prostate, pancreatic and ovarian cancers.

Fairly Valued

The company’s latest PE is -5.64, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 3.54M shares, increasing 9.92% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 666.80K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.21.

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change

0



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

The company’s current valuation score is 6.14, which is lower than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -5.64, which is -31.30% below the recent high of -3.88 and -123.18% above the recent low of -12.59.

Score

Industry at a Glance

Previous score

6.14

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 238/501

No Data

The company’s current earnings forecast score is 8.33, which is higher than the Biotechnology & Medical Research industry's average of 8.04. The average price target for Nuvectis Pharma Inc is 18.50, with a high of 25.00 and a low of 10.00.

Score

Industry at a Glance

Previous score

8.33

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 8.56, which is higher than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 6.90 and the support level at 5.91, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.40

Change

2.16

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated: 2025-10-27

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 13.91%, representing a quarter-over-quarter decrease of 74.06%. The largest institutional shareholder is The Vanguard, holding a total of 666.80K shares, representing 2.62% of shares outstanding, with 56.98% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Bentsur (Ron)

3.52M

--

Mosseri Marlio (Charles)

2.88M

+9.08%

Poradosu (Enrique)

1.66M

--

Shemesh (Shay)

1.64M

--

The Vanguard Group, Inc.

Star Investors

666.80K

+42.66%

BlackRock Institutional Trust Company, N.A.

575.49K

+940.81%

Iridian Asset Management LLC

372.72K

+46.76%

Baldwin Wealth Partners, LLC

350.46K

-2.23%

Pontifax Venture Capital

288.87K

-68.51%

Geode Capital Management, L.L.C.

285.33K

+110.84%



1

2



There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is -0.30. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Nuvectis Pharma Inc

NVCT

4.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

CytomX Therapeutics Inc

CTMX

8.50 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.50 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Insmed Inc

INSM

8.49 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

MDGL

8.46 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Dynavax Technologies Corp

DVAX

8.41 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment